Treatment of Mooren’s Ulcer with Topical Administration of Interferon Alfa 2a
Received 14 February 2006; accepted 28 September 2006. published online 02 January 2007.
Objective
To report an apparently beneficial effect of topical interferon alfa 2a (IFNα2a) as a single therapeutic agent in the treatment of Mooren’s ulcer.
Design
Two case reports.
Participants
Two consecutive patients with unilateral Mooren’s ulcer diagnosed at the cornea service of Gulhane Military Medical Academy from December 2004 to December 2005 were studied retrospectively.
Intervention
Patients with a clinical diagnosis of Mooren’s ulcer were treated with topical IFNα2a until their lesions resolved.
Main Outcome Measures
A review of medical records was performed to assess the duration and response to treatment with topical IFNα2a drops, defined by clinical resolution of Mooren’s ulcer.
Results
Symptoms and signs in 2 eyes improved during the first week of treatment, and reepithelialization was achieved at 7 and 10 days. Visual acuity levels reached 20/25 and 20/30 within 1 month of treatment. No recurrences were observed during 1 year and 6 months of follow up.
Conclusions
Topical IFNα2a as a single therapeutic agent was an effective alternative in the treatment of our 2 patients with Mooren’s ulcer. It offers the benefits of topical therapy and avoided surgical or other interventions that may lead to stem cell deficiency. Larger controlled studies are necessary to confirm the long-term efficacy and safety of this treatment.
Department of Ophthalmology, Gülhane Military Medical Academy, Ankara, Turkey.
Correspondence to Uzeyir Erdem, MD, Cornea and Refractive Surgery Department, GATA Goz AD 06018, Etlik, Ankara, Turkey.
Manuscript no. 2006-191.
No author has a financial or proprietary interest in any material or method mentioned in the article.
ABSTRACT